- Home
- CLDX vs BHVN Comparison
CLDX vs BHVN Comparison
Compare CLDX & BHVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CLDX | BHVN |
|---|---|---|
| Founded | N/A | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 1.6B |
| IPO Year | 1995 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CLDX | BHVN |
|---|---|---|
| Price | $29.00 | $10.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 10 | 14 |
| Target Price | ★ $44.50 | $27.69 |
| AVG Volume (30 Days) | 813.3K | ★ 1.9M |
| Earning Date | 05-28-2026 | 06-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 26.08 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $12,743,000.00 | N/A |
| Revenue This Year | $97.61 | N/A |
| Revenue Next Year | $252.01 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 87.78 | N/A |
| 52 Week Low | $14.40 | $7.48 |
| 52 Week High | $31.31 | $31.87 |
Technical Indicators
Market Signals| Indicator | CLDX | BHVN |
|---|---|---|
| Relative Strength Index (RSI) | 63.68 | 42.16 |
| Support Level | $24.70 | $10.75 |
| Resistance Level | $30.50 | $15.66 |
| Average True Range (ATR) | 1.52 | 0.65 |
| MACD | 0.78 | -0.07 |
| Stochastic Oscillator | 77.87 | 12.74 |
Price Performance
Historical ComparisonAbout CLDX Celldex Therapeutics Inc.
Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. It has single operating and reportable segment that operates in the business of development, manufacturing and commercialization of novel therapeutics for human health care.
About BHVN Biohaven Ltd.
Biohaven Ltd is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of life-changing treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Its product pipeline includes Glutamate, Myostatin, Ion channels, Inflammation & Immunology, and Oncology. The company's products target diseases such as neuromuscular and metabolic diseases, antibody-drug conjugates for cancer, obsessive-compulsive disorder, and others.